Objective: With the advent of highly active antiretroviral therapy regimens, it is crucial to consider their long-term benefits to risk ratios among HIV-infected persons. The impact of protease inhibitors on the cardiovascular risk is controversial.
Introduction
With the advent of HAART regimens, it is crucial to consider their long-term benefits to risk ratios in HIVinfected patients. If the high cardiovascular risk among these patients is no longer discussed [1, 2] , the mechanism is controversial: (1) the consequence of an HIV-associated chronic inflammation [3] [4] [5] [6] [7] , of dysimmunity [8] [9] [10] , or of co-infection [11] ; (2) a high frequency of standard risk factors (sex, smoking, etc.) among HIV-infected population [8, 12, 13] . However, the Framingham risk score underestimates subclinical atherosclerosis observed in HIV-infected population [14] ; (3) HAART-induced metabolic abnormalities [7, 15] , especially with protease inhibitor [16] , even a metabolic syndrome [17, 18] , lipodystrophy [19] , endothelial dysfunction [20, 21] , or acquired thrombophilia [22] , even though the impact of confounders is discussed [13, 23, 24] . In this case, apart from the usual healthy lifestyle recommendations [25] (giving up smoking, diet, physical exercise), the interventional strategy is not clear: switching from a HAART regimen generally active and well accepted to a new regimen [26] , which induces less metabolic abnormalities but without assurance of a favorable clinical impact [27] ; giving a specific treatment (statins [28] , salicylic acid [22, 27] ), or only cardiovascular monitoring.
Since 2003, thanks to atazanavir (ATV), a new protease inhibitor, it is possible to assess the impact of a protease inhibitor-containing HAART regimen that does not provide major dyslipidemia [29] or insulin resistance [30] thanks to a validated surrogate investigator of atherosclerosis: the carotid intima-media thickness (cIMT).
Methods

Design
This hospital-based single-center observational, comparative, prospective cohort study (AVATAR: atazanavir versus other antiretroviral therapy and atherosclerosis research) was approved by the institutional review committee and took place from January 2004 to January 2008.
First objective
To compare cIMT evolution between patients with and without ATV exposure.
Second objective
To adjust according to significantly different variables such as HIV, cardiovascular, or demographic status.
Population
Among the 229 HIV-infected adults from the Brest Hospital University Cohort, 33 patients (cases) treated by HAART regimen including ritonavir-boosted ATV (ATV/r) were compared with 99 age-matched (<2 years) and sex-matched controls without ATV/r exposure.
Collected data
The data was collected blindly, cIMT included, and under informed consent.
Conventional atherosclerosis risk factors status Age, sex, prior smoking (in pack-years), family history of cardiovascular disease (CVD) (in percentage of firstdegree relatives), current cardiovascular therapy (hypolipemiant, antidiabetic, antiplatelet, or antihypertensive treatment), waist perimeter, BMI, SBP and DBP, and usual blood analysis, after overnight fasting (>12 h), of total and high-density lipoprotein (HDL) cholesterol, glucose, and triglycerides. The Framingham risk score [31] and the NCEP-ATP-III Metabolic Syndrome status [32] were calculated for each patient.
HIV status
The likely onset of infection, the CD4 cell count, the viral load, the current (HAART regimen at the baseline) and cumulated (addition of the cumulative time (in days) of exposure to all drugs of each class) exposure to nucleosidic reverse transcriptase inhibitors (NRTIs) or nonnucleosidic reverse transcriptase inhibitors (NNRTIs) and protease inhibitor (baby-dose not considered).
Measurement of carotid intima-media thickness
cIMT was measured at the baseline, 6, 12, and 18 months, using a bidimensional ultrasonography on an ATL HDI 5000 apparatus combined with a linear broadband transducer (L 12-7) (Philips, Eindhoven, the Netherlands). The measurement site was the common carotid artery posterior wall (left and right for each patient), 1 cm from the carotid bifurcation over at least a 1-cm-long distance, 35 mm deep. The measurement was carried out at the end of a diastole and the segment length, the mean IMT, and in addition, the minimal and maximal IMT values, the standard deviation, and a quality index were determined on a Metris station (Metris, Argenteuil, France) without manual correction. The intra-operator variability was characterized by an R 2 of 0.82 (n ¼ 57).
Sample size estimation
When taking into account a cIMT increase of 0.05 mm/ year [8] , the impact of a ATV/r switch similar to statin use (À0.04 mm/year) [33] and a variance of 0.09 mm (as observed in SHIVA study conducted in the same population 1 year before [34] ), 33 cases and 99 matched controls followed up over 18 months were required to obtain a power of 80% with an alpha risk of 5%. Comparison of main characteristics between 97 not included and 132 included (data not showed) patients at the baseline, and between 33 boosted Atazanavir (cases) and 99 not Atazanavir (age (<2 years) and sex matched controls) exposed patients at the baseline and during the follow-up. Except if specified, the data were expressed as mean and standard deviation (in brackets). CVD, cardiovascular disease; NNRTI, nonnucleosidic reverse transcriptase inhibitor; NRTI, nucleosidic reverse transcriptase inhibitor; NS, not significant (P > 0.05).
course, the protease inhibitor and NNRTI exposure were different between both groups, the cases being exclusively exposed to ATV/r, while the NRTI exposure was the same. Nevertheless, the use of a once-a-day drug (didanosine or tenofovir) was more frequent with ATV/ r-based regimen than with zidovudine ( Table 2 , http:// links.lww.com/QAD/A92). Ten controls (10.1%) did not receive HAART during the study; the three others were treated by boosted ATV/r and NRTI, 162, 186, and 504 days after inclusion, respectively. For two of them, two cIMT measures were missing.
Exposure to cardiovascular drugs was the same before and during the study ( Table 2 , http://links.lww.com/QAD/ A92).
Although not different at inclusion (0.633 AE 0.05 in cases vs. 0.666 AE À0.09 in controls, P ¼ 0.07), the cIMT significantly decreased at 12 (0.636 vs. 0.676; P ¼ 0.05) and 18 months (0.611 vs. 0.675, P ¼ 0.018), but not at 6 months (0.642 vs. 0.660) in cases when compared to controls ( Fig. 1) . After adjustment by the variables that differed between cases and controls (P < 0.1) at inclusion (HDL-c, cardiovascular family history) and the protease inhibitor, NRTI, and NNRTI cumulated and current exposures, the differences remain significant.
Discussion
The cIMT, a well known and validated surrogate marker of atherosclerosis, decreased significantly among patients on the HAART regimen including ATV/r, whereas a slight increase is observed in the control group. This difference in the cIMT course appeared after 6 months of follow-up, when the cases had been ATV/r exposed since 289 days. The HIV and cardiovascular baseline characteristics were similar and these results did not change after the planned adjustments. The glycemia, the only parameter significantly different during the study (À0.44 mmol/l in case group), had no impact on the cIMT difference observed between cases and controls.
However, this study has some limitations. First, the study was not randomized. Thus, it is impossible to exclude the hypothesis that the ATV/r regimen may have been especially prescribed to patients with a high vascular risk, even though the cardiovascular baseline characteristics, including the Framingham score, the metabolic syndrome status, cardiovascular treatments, and cIMT were not significantly different. Incidentally, with larger samples, the baseline characteristics might have been different. Moreover, this modification in the HAART regimen could have been brought about by diet or physical activity recommendations, two relevant parameters, which were not collected in our study.
On the contrary, the heterogeneity of the control group should lead to sub-analyses according to the different HAART regimens. However, sufficient statistical power cannot be attained due to the small size of the samples. Moreover, the insufficient number of cases and controls, particularly at the end of the study, could explain why the mechanisms of the positive impact of ATV/r remain unclear. In fact, a major metabolic change is not obvious.
Thus, if an interventional correction of the cardiovascular risk is necessary, the results of the AVATAR study favor a switch to a low cardiovascular impact HAART regimen, like HAART including ATV/r, which amounts to the usual cardiovascular prevention. Of course, these data must be confirmed by further randomized studies. Fig. 1 . Comparison of the course (baseline (M0), 3, 12, and 18 months) of the carotid intima-media thickness (cIMT) (mean and 95% CI) between the ATV/r exposed (cases) and the age-and sex-matched not exposed (controls) patients. Posthoc power is a nonplanned estimation.
